A new study reveals a COVID-19 vaccine under development in England safely promotes an immune response against the virus.
According to UPI, the vaccine is in Phase 2 of clinical trials with Astra Zeneca, and is particularly effective in elderly recipients who are over age 70.
Researchers say the finding of the 'robust' responses in older people in their study is both significant and encouraging.
The populations at greatest risk of serious COVID-19 disease include people with existing health conditions and older adults.
The so-called "Oxford vaccine," formally known as ChAdOx1 nCoV-19, is one of more than 120 being evaluated in response to the COVID-19 pandemic.
To date, 48 of these vaccines have gotten into clinical trials to assess their safety and efficacy.